

DOSAGE FORM DESIGN

Abstract

The design of dosage forms plays a critical role in the development and delivery of pharmaceutical products. It involves the careful selection and combination of excipients, drug substances, and manufacturing processes to create safe, effective, and patient-friendly dosage forms. This abstract provides an overview of the key considerations and principles involved in the design of dosage forms. The design process begins with a thorough understanding of the physicochemical properties of the drug substance, such as solubility, stability, and bioavailability. This knowledge guides the selection of appropriate formulation strategies and excipients to optimize drug delivery. Different dosage forms, such as tablets, capsules, injections, creams, and inhalers, have specific requirements and challenges that must be addressed during the design process. The choice of excipients is crucial in dosage form design, as they can affect the drug's stability, dissolution, and absorption characteristics. Excipients may include binders, disintegrants, lubricants, fillers, and coatings, among others. Careful consideration must be given to their compatibility with the drug substance and their impact on the overall product performance. Manufacturing processes also play a vital role in dosage form design. Various techniques, such as wet granulation, dry granulation, compression, and film coating, are employed to produce dosage forms with the desired characteristics. Process parameters, such as mixing time, compression force, and drying conditions, need to be optimized to ensure batch-to-batch consistency and product quality. Furthermore, regulatory requirements and quality standards must be considered throughout the design process. Dosage forms must comply with regulatory guidelines

Authors

Dr. Garima Verma

Faculty of Pharmacy
Swami Vivekanand Subharti University
Meerut, UP, India.

Dr. Ajay Kumar Shukla

Institute of Pharmacy
Dr Ram Manohar Lohia Awadh University.
Ayodhya, UP, India.

Dr. Vimal Kumar Yadav

Institute of Pharmacy
Dr Ram Manohar Lohia Awadh University.
Ayodhya, UP, India.

regarding safety, efficacy, labeling, and packaging. Good Manufacturing Practices (GMP) principles are employed to ensure consistent product quality, process robustness, and traceability. The design of dosage forms involves a multidisciplinary approach, combining knowledge of drug substances, excipients, formulation strategies, manufacturing processes, patient needs, and regulatory requirements. By carefully considering these factors, pharmaceutical scientists can develop dosage forms that deliver drugs effectively, safely, and conveniently, ultimately improving patient outcomes.

Keywords: design of dosage forms, Good Manufacturing Practices (GMP), Biopharmaceutical, Drug factors in dosage form design

I. PRINCIPLES OF DOSAGE FORM DESIGN

Drugs are rarely administered as pure chemical substances alone and are almost always given as formulated preparations or medicines. These can vary from relatively simple solutions to complex drug delivery systems through the use of appropriate additives or excipients in the formulations. The excipients provide varied and specialized pharmaceutical functions. It is the formulation additives that, amongst other things, solubilize, suspend, thicken, preserve, emulsify, modify dissolution, improve the compactability and flavour drug substances to form various medicines or dosage forms. Pharmaceutical drugs are typically administered in the form of formulated preparations or medicines, rather than as pure chemical substances in isolation. These preparations can range from simple solutions to complex drug delivery systems, achieved by incorporating appropriate additives or excipients into the formulations. The purpose of these excipients is to provide various specialized functions in the pharmaceutical context. For instance, they can solubilize, suspend, thicken, preserve, emulsify, modify dissolution, improve compactability, and enhance the flavor of drug substances, ultimately leading to the formation of different medicines or dosage forms (Aulton 2002).

The primary goal of designing dosage forms is to achieve a consistent therapeutic response to a drug included in a formulation that can be manufactured on a large scale while ensuring reproducible product quality. Several key features are necessary to guarantee product quality. These include chemical and physical stability, appropriate protection against microbial contamination when necessary, uniformity in drug dosage, acceptability to both prescribers and patients, and suitable packaging and labeling. Ideally, dosage forms should also be unaffected by variations between individual patients, although accomplishing this in practice remains challenging. Nevertheless, recent advancements are starting to address this requirement. Examples include drug delivery systems that rely on the specific metabolic activity of individual patients and implants that respond to external stimuli such as sound or magnetic fields to initiate drug release mechanisms (Brahmankar 2015).

The investigation of differences in drug bioavailability and bio-fate among seemingly similar formulations and their potential causes should be given careful consideration. In recent years, there has been an increasing focus on reducing variability in the bioavailability characteristics of medicinal products that contain the same dose of a drug substance. This recognition stems from the understanding that formulation factors can impact the therapeutic performance of these products. To enhance the bioavailability of drug substances, it is often necessary to meticulously select the most suitable chemical form of the drug. This selection process should take into account factors such as solubility requirements, drug particle size, physical form, as well as the inclusion of appropriate additives and manufacturing aids. In addition to these considerations, the choice of administration route(s) and dosage form(s) must also be taken into account. Furthermore, appropriate manufacturing processes, labeling, and packaging are essential components in optimizing drug bioavailability (Ho WH 1987).

There exist multiple pharmaceutical formulations that incorporate drug substances, aiming to provide convenient and effective treatment for various diseases. These dosage forms can be tailored for administration through diverse delivery routes in order to maximize the therapeutic response. Examples include oral ingestion, injection, topical application, and inhalation, as detailed in Table 1.1, which enumerates the range of dosage forms applicable to each administration route. However, it is imperative to consider the relationship between the

drug substance and the clinical indication being treated in order to determine the appropriate combination of drug and dosage form. Each disease or illness typically necessitates a specific type of drug therapy. Furthermore, when designing dosage forms, it is important to consider the factors influencing the choice of administration route as well as the specific requirements of that route, which can impact drug absorption (Jain 1997).

Table 1.1: Dosage forms available for different administration routes

Administration route	Dosage forms
Oral	Solutions, syrups, suspensions, emulsions, gels, powders, granules, capsules, tablets
Rectal	Suppositories, ointments, creams, powders, solutions
Topical	Ointments, creams, pastes, lotions, gels, solutions, topical aerosols, foams, transdermal patches
Parenteral	Injections (solution, suspension, emulsion forms), implants, irrigation and dialysis solutions
Respiratory	Aerosols (solution, suspension, emulsion, powder forms), inhalations, sprays, gases
Nasal	Solutions, inhalations
Eye	Solutions, ointments, creams
Ear	Solutions, suspensions, ointments, creams

Multiple pharmaceutical dosage forms with different strengths are developed for various drugs, each possessing specific pharmaceutical properties suitable for particular applications. One such drug is prednisolone, a glucocorticoid employed for suppressing inflammatory and allergic disorders. By employing diverse chemical forms and formulation additives, a variety of effective anti-inflammatory preparations are accessible, including tablets, enteric-coated tablets, injections, eye drops, and enemas. The exceptionally low solubility of prednisolone in water, as well as its acetate salt, render these forms advantageous for tablet and slowly absorbed intramuscular suspension injection formats. Conversely, the soluble sodium phosphate salt allows for the preparation of soluble tablets, solutions for eye and ear drops, enemas, and intravenous injections. Similarly, the analgesic paracetamol is available in multiple dosage forms and strengths to cater to the specific requirements of users, including tablets, dispersible tablets, pediatric soluble tablets, pediatric oral solution, sugar-free oral solution, oral suspension, double-strength oral suspension, and suppositories (Kumar 2010).

Moreover, while there continues to be a constant discovery and transformation of new drugs based on low molecular weight organic compounds into medicinal products, there is a growing trend in the development of drugs derived from biotechnology. These biotechnological therapeutic agents, which are macromolecular and possess relatively large molecular weights, encompass substances such as peptides, proteins, and viral components. The formulation and processing of these drug substances into medicines pose intricate challenges due to their diverse biological, chemical, and structural properties. However, the fundamental principles of designing dosage forms still apply. Currently, these therapeutic agents are primarily formulated into parenteral and respiratory dosage forms, although other routes of administration are being explored and studied. The delivery of these

biotechnologically-based drug substances through these administration routes introduces additional limitations in the selection of suitable formulation excipients.

It is therefore apparent that before a drug substance can be successfully formulated into a dosage form, many factors must be considered. These can be broadly grouped into three categories:

1. Factors impacting the absorption of the therapeutic material from various administration methods, as well as other biopharmaceutical concerns
2. The physical and chemical characteristics of the drug substance, such as the drug factor
3. Therapeutic aspects, such as taking into account the patient's characteristics and the clinical indication that needs to be addressed.

Only when all of these elements are taken into account and connected to one another can high-quality, effective medicines be developed and made. This is the fundamental idea behind dosage form design (Robinson 1987).

II. BIOPHARMACEUTICAL ASPECTS OF DOSAGE FORM DESIGN

Biopharmaceutics encompasses the examination of the interplay between the physical, chemical, and biological sciences as they pertain to drugs, dosage forms, and their effects. A comprehensive understanding of this field is crucial for the development of dosage forms, particularly in relation to drug absorption, distribution, metabolism, and excretion. In general, for a drug to be absorbed into the body fluids, it must first be in a solubilized state, allowing passage through absorbing membranes and epithelia present in the skin, gastrointestinal tract, and lungs. Drug absorption occurs through two primary mechanisms: passive diffusion and carrier-mediated transport. Passive diffusion, which is responsible for the absorption of many drugs, relies on the concentration gradient across cellular barriers, with drug molecules moving from regions of high concentration to regions of low concentration. The rate of diffusion is influenced by factors such as lipid solubility and the degree of ionization of the drug at the absorption site. Recent research on carrier-mediated transport mechanisms has yielded valuable insights and knowledge, aiding in the design of new drug molecules in certain cases. Various specialized transport mechanisms, including active and facilitated transport, have been postulated. Following absorption, the drug can exert its therapeutic effect either locally or at a distant site of action, separate from the administration site. In the latter case, the drug has to be transported in body fluids (as shown in [Figure 1.1](#)). (Brahmankar 2015, Amidon 1995).




Figure 1: Pathways a drug may take following the administration of a dosage form by different routes.

When the pharmaceutical formulation is designed for drug administration through the buccal, respiratory, rectal, intramuscular, or subcutaneous routes, the drug directly enters the systemic circulation by being absorbed through the respective tissues. Among these routes, the intravenous route offers the most direct path for drug delivery. In contrast, when drugs are administered orally, the onset of drug action is delayed due to the necessary transit time in the gastrointestinal tract before absorption can occur. The absorption process is influenced by various factors, including hepatic and intestinal blood circulation. Additionally, the physical form of the oral dosage form can affect the rate of absorption and the time it takes for the drug to exert its therapeutic effects. Solutions typically act faster than suspensions, which, in turn, generally act faster than capsules and tablets. Consequently, dosage forms can be ranked according to the time required for the onset of therapeutic effects (refer to Table 1.2). Nonetheless, regardless of the delivery route, all drugs are considered foreign substances to the human body. Thus, distribution, metabolic transformation, and elimination processes begin immediately after drug absorption and continue until the drug is eliminated from the body, either unchanged or in a metabolized form, through urine, feces, saliva, skin, or lungs (Robinson 1987, Shukla 2017).

Table 1.2 Variation in time of onset of action for different dosage forms

Time of onset of action	Dosage forms
Seconds	Intravenous injections
Minutes	Intramuscular and subcutaneous injections, buccal tablets, aerosols, gases
Minutes to hours	Short-term depot injections, solutions, suspensions, powders, granules, capsules, tablets, modified-release tablets
Several hours	Enteric-coated formulations
Days to weeks	Depot injections, implants
Varies	Topical preparations

III. ROUTES OF DRUG ADMINISTRATION

The way that medications are absorbed varies greatly depending on the specific drug substance as well as the method of delivery. The purpose of dosage forms is to provide the medication in a way that will allow it to be absorbed through the chosen route of administration. While dose forms are addressed, the following section briefly examines the methods of drug administration (Vyas 2002, Shukla 2017, 2018).

1. Oral route: The oral route is the predominant method of administering drugs and is widely utilized in medical practice. Oral dosage forms are primarily designed for achieving systemic effects through the absorption of drugs across the various epithelial and mucosal barriers of the gastrointestinal tract. In some cases, certain drugs are intended to dissolve in the mouth for rapid absorption or to exert a localized effect within the gastrointestinal tract due to their poor absorption via the oral route or limited solubility in water. Comparatively, among the various routes of drug administration, the oral route is considered the simplest, most convenient, and safest. Nonetheless, there are drawbacks associated with this route, including a relatively slow onset of action, the possibility of inconsistent drug absorption, and the potential degradation of specific drugs by enzymes and secretions present in the gastrointestinal tract. To illustrate, preparations containing insulin are rendered ineffective due to the actions of stomach fluids.

While drug absorption from the gastrointestinal tract generally adheres to the principles outlined in this book, it is crucial to highlight several specific aspects. Changes in drug solubility may occur due to interactions with other substances present in the gastrointestinal tract. For instance, the absorption of tetracyclines may be hindered by the formation of insoluble complexes with calcium, which can originate from food or additives in the formulation. The rate at which the stomach empties its contents significantly influences the effective absorption of drugs from the intestine. Slow gastric emptying can be disadvantageous for drugs that are susceptible to inactivation by gastric juices, as it can delay their absorption, particularly for drugs that are better absorbed from the intestine. Moreover, the environmental pH along the gastrointestinal tract plays a vital

role in the ionization and lipid solubility of drugs. The pH gradient from the highly acidic stomach (pH as low as 1) to the approximately neutral or slightly alkaline conditions in the large intestine (pH around 7 or 8) affects both the extent and site of drug absorption. Since membranes exhibit greater permeability to unionized forms rather than ionized forms, and considering that most drugs are weak acids or bases, it is evident that weak acids, predominantly in their unionized state, are readily absorbed from the stomach. In the small intestine (pH ranging from approximately 4 to 6.5), characterized by a vast absorptive surface, both weak acids and weak bases are well absorbed.

The oral administration of medications is commonly facilitated through various dosage forms, with tablets, capsules, suspensions, solutions, and emulsions being the most prevalent. Tablets are formulated by compacting drugs and additional substances with specific functions. These substances, such as disintegrants, aid in the breakdown of tablets into granules and powder particles within the gastrointestinal tract. This breakdown process enhances drug dissolution and absorption. Tablets are often coated to serve different purposes, including protecting the drug from environmental factors for stability reasons, masking unpleasant taste, and safeguarding against stomach acidity through enteric coating. Modified-release tablet products, such as fast-dissolving systems and controlled, delayed, or sustained-release formulations, are increasingly utilized. Controlled-release tablets, achieved through polymeric-based cores or coating membranes, offer advantages such as decreased occurrence of drug-related side effects and the maintenance of steady drug levels in the bloodstream over prolonged periods. These benefits are particularly significant for chronic conditions and situations requiring consistent drug levels to achieve optimal effectiveness, such as the treatment of angina and hypertension.

IV. DRUG FACTORS IN DOSAGE FORM DESIGN

Dosage form design plays a pivotal role in ensuring the safe and effective delivery of drugs to patients. It involves the integration of various drug-related factors, such as physicochemical properties, stability, bioavailability, and therapeutic objectives, into the formulation design. This note aims to provide a detailed scientific perspective on the crucial drug factors that influence dosage form design (Aulton 2002)

Physicochemical properties: The physicochemical properties of a drug significantly impact its dosage form design. Parameters such as solubility, particle size, polymorphism, and crystal habit influence the dissolution rate, stability, and bioavailability of the drug. For instance, drugs with poor solubility may require formulation strategies like nanosuspensions, cyclodextrin complexes, or lipid-based delivery systems to enhance their solubility and absorption. Dosage form design involves the development of pharmaceutical formulations that ensure the controlled release and targeted delivery of drugs to achieve desired therapeutic effects. Particle size and surface area, inherent characteristics of drug substances and excipients, have been recognized as critical factors influencing various drug-related factors such as dissolution rate, bioavailability, stability, and manufacturability (Brahmankar 2015, Conradi 1996)

V. PARTICLE SIZE AND DISSOLUTION RATE

The particle size of a drug in a dosage form significantly affects its dissolution rate. Fine particles possess larger surface areas, facilitating faster dissolution compared to coarse particles. The increased surface area allows for greater contact with the dissolution medium, resulting in improved drug release kinetics. Consequently, drugs with smaller particle sizes exhibit enhanced bioavailability and more predictable pharmacokinetics.

- 1. Surface Area and Bioavailability:** The surface area of drug particles is directly proportional to their bioavailability. Increased surface area facilitates better absorption, as the drug molecules have a larger area available for interaction with the absorptive surfaces in the gastrointestinal tract. Consequently, formulations with smaller particle sizes often exhibit improved bioavailability, leading to optimized therapeutic outcomes.
- 2. Stability Considerations:** Particle size also influences drug stability. Smaller particles may be more susceptible to degradation or chemical reactions due to their increased surface area and higher reactivity. Therefore, careful consideration must be given to particle size during dosage form design to ensure adequate stability throughout the product's shelf life.
- 3. Manufacturability and Particle Size: Particle size plays a Crucial role in the** manufacturability of dosage forms. Fine particles may pose challenges during formulation development, such as powder flowability, content uniformity, and processability. Conversely, larger particles may result in poor compaction properties and hinder tablet formation. Therefore, a balance between particle size and manufacturability must be achieved to optimize the dosage form design.
- 4. Particle Size Reduction Techniques:** Various techniques are employed to control and reduce the particle size of drug substances, including milling, micronization, spray drying, and nanotechnology-based approaches. These methods offer precise control over particle size and surface area, allowing for tailored drug release profiles and improved therapeutic outcomes.

Particle size and surface area are vital parameters in dosage form design, influencing drug dissolution rate, bioavailability, stability, and manufacturability. Understanding the relationship between particle size, surface area, and drug-related factors provides a scientific foundation for optimizing drug formulations and enhancing therapeutic efficacy. By employing appropriate particle size reduction techniques, researchers and formulation scientists can design dosage forms that meet the specific requirements of various drug substances, leading to improved patient outcomes and overall healthcare (Conradi 1996).

- 5. Bioavailability:** Bioavailability refers to the extent and rate at which a drug reaches the systemic circulation to produce its pharmacological effect. Several factors are including drug solubility, permeability, and metabolism, influence bioavailability. Dosage forms must be designed to optimize these factors. Techniques such as solid dispersion, complexation, prodrug formation, and formulation of lipid-based drug delivery systems can enhance drug bioavailability (Lobenberg 2000).

- 6. Therapeutic Objectives:** The therapeutic objectives of a drug also influence dosage form design. These objectives may include sustained release, targeted delivery, or immediate release formulations. Sustained release dosage forms are designed to release the drug slowly over an extended period, maintaining therapeutic concentrations. Targeted delivery systems aim to deliver drugs to specific sites within the body, minimizing systemic exposure. Immediate release formulations are designed for drugs requiring rapid onset of action.

The design of dosage forms is a complex process influenced by various drug-related factors. Physicochemical properties, stability, bioavailability, and therapeutic objectives all play integral roles in determining the optimal formulation strategy. Understanding and considering these factors are crucial for developing safe, effective, and patient-centric drug products. Continuous research and advancements in pharmaceutical sciences contribute to the refinement of dosage form design, ultimately leading to improved drug therapy outcomes (Camenisch 1996).

VI. SOLUBILITY

Dosage form design plays a critical role in pharmaceutical development, as it directly affects drug efficacy and patient compliance. One key factor in dosage form design is the solubility of the active pharmaceutical ingredient (API). The solubility of a drug influences its dissolution rate, bioavailability, and ultimately, its therapeutic effectiveness. This note aims to explore the intricate relationship between drug factors and dosage form design, specifically focusing on the impact of solubility (Lennernäs 1997)

Drug Factors Affecting Solubility

- 1. Chemical Structure:** The chemical structure of a drug significantly affects its solubility characteristics. Functional groups, such as hydroxyl (-OH), amino (-NH₂), and carboxyl (-COOH), can either enhance or hinder solubility depending on their position and interaction with the solvent. Furthermore, the presence of ionizable groups can significantly impact solubility by altering the drug's ionization state.
- 2. Molecular Weight:** The molecular weight of a drug also plays a crucial role in solubility. Generally, lower molecular weight compounds tend to have better solubility than larger molecules. This can be attributed to the increased surface area-to-volume ratio, facilitating interactions with the solvent molecules.
- 3. Polymorphism:** Polymorphism refers to the ability of a drug to exist in different crystal forms. Each polymorphic form can exhibit distinct solubility characteristics due to differences in crystal lattice arrangement and intermolecular forces. Polymorph selection is, therefore, a crucial consideration in dosage form design to ensure optimal solubility and stability.
- 4. Lipophilicity:** The lipophilicity, or hydrophobicity, of a drug influences its solubility in different media. Lipophilic drugs tend to have higher solubility in non-polar solvents but exhibit poor solubility in aqueous solutions. Lipophilicity affects the choice of excipients and formulation strategies employed to enhance drug solubility.

5. **Salt Formation:** Converting a drug into its salt form can significantly impact its solubility. Salt formation can increase solubility by introducing ionic interactions, altering the drug's ionization state, and modifying its crystal lattice structure (Goodwin 2001)
6. **Co-solvents and Surfactants:** Co-solvents and surfactants are commonly used to enhance the solubility of poorly soluble drugs. Co-solvents can improve solubility by increasing the drug's solvation capacity, while surfactants can aid in dispersing the drug in the dissolution medium, facilitating dissolution.
7. **Particle Size Reduction:** Reducing the particle size of a drug can greatly increase its surface area, leading to improved dissolution and solubility. Techniques such as micronization, nanosizing, and amorphous solid dispersion formation are utilized to achieve particle size reduction and enhance drug solubility.
8. **pH Adjustment:** Altering the pH of the dissolution medium can significantly impact drug solubility, especially for ionizable drugs. pH adjustment can enhance or reduce solubility by shifting the drug's ionization equilibrium and optimizing its solubility in specific regions of the gastrointestinal tract.

The solubility of a drug is a critical consideration in dosage form design, as it directly influences drug dissolution, absorption, and therapeutic efficacy. By understanding the drug factors that affect solubility, pharmaceutical scientists can employ various formulation strategies to optimize drug solubility and enhance the performance of dosage forms. Achieving an optimal balance between drug properties and dosage form design is essential for the development of safe, effective, and patient-friendly pharmaceutical products

VII. DISSOLUTION

Drug Factors Affecting Dissolution

1. Physicochemical Properties:

- **Solubility:** The solubility of a drug in the surrounding medium is a key determinant of its dissolution rate. Highly soluble drugs generally exhibit rapid dissolution, while poorly soluble drugs may exhibit slower dissolution profiles (Goodwin 2000, Leuner 2000)
- **Particle Size:** The particle size of a drug can significantly influence its dissolution. Reduction in particle size increases the surface area available for dissolution, leading to faster dissolution rates.
- **Polymorphism:** Different crystal forms or polymorphs of a drug can exhibit distinct dissolution characteristics. Polymorphic transformations during dissolution can impact the dissolution rate and subsequent bioavailability of the drug (Goodwin 2000, Leuner 2000).

- **Lipophilicity:** The lipophilic nature of a drug affects its solubility in lipid-based dosage forms, such as emulsions or lipid-based nanoparticles. Lipophilic drugs tend to dissolve more readily in lipid matrices, enhancing their dissolution rates.
- **Ionization:** The ionization state of a drug molecule in a specific pH environment can influence its solubility and subsequent dissolution. Ionized forms of a drug may exhibit altered dissolution profiles compared to their non-ionized counterparts (Goodwin 2000, Leuner 2000, Charman 1997)
- **Excipients:** The choice and concentration of excipients in a dosage form can influence drug dissolution. Excipients such as surfactants, solubilizers, and pH modifiers can enhance or hinder drug solubility and dissolution rates
- **Matrix Properties:** The composition and structure of matrices in controlled-release dosage forms impact drug dissolution. Matrix systems with sustained release properties may alter the dissolution profile by controlling drug release over an extended period (Charman 1997).

2. Dissolution enhancement Strategies

- **Particle Size Reduction:** Techniques like micronization, nanosizing, or amorphous solid dispersion formation can enhance drug dissolution by increasing the surface area available for dissolution (Conradi 1996)
- **Salt Formation:** Converting a drug into a salt form can improve its solubility and dissolution characteristics, leading to enhanced bioavailability.
- **Lipid-Based Formulations:** Lipid-based dosage forms, such as lipid emulsions or self-emulsifying systems, can enhance the dissolution of lipophilic drugs by improving their solubility in lipid matrices.
- **pH Adjustment:** Modifying the pH of the dissolution medium or incorporating pH-modifying excipients in the formulation can optimize drug solubility and dissolution profiles for ionizable drugs.
- **Controlled-Release Systems:** Designing dosage forms with sustained-release properties, such as hydrogels or osmotic systems, can regulate drug release and dissolution rates, ensuring prolonged therapeutic action.

The dissolution of drugs from dosage forms is influenced by various drug-related factors, including physicochemical properties, chemical structure, and formulation characteristics. Understanding these factors and employing appropriate dosage form design strategies can optimize drug dissolution rates and subsequent bioavailability. By fine-tuning the interplay between drug properties and formulation design, pharmaceutical scientists can enhance the therapeutic efficacy and patient outcomes of orally administered drugs.

VIII. PARTITION COEFFICIENT AND PKA

In the field of pharmaceutical sciences, the design of dosage forms plays a critical role in ensuring optimal drug delivery and therapeutic efficacy. Among the various factors considered during the formulation process, the partition coefficient (P) and the acid dissociation constant (pKa) of a drug are of particular significance. This note aims to delve into the scientific relationship between these two drug factors and their influence on dosage form design (Banker 2008, Nai-Ning 2004)

- 1. Partition Coefficient (P):** The partition coefficient, denoted as P, is a measure of the distribution of a drug between two immiscible phases, typically an organic solvent and an aqueous solution. It quantifies the lipophilicity or hydrophilicity of a compound, indicating its affinity for lipid-based or water-based environments. The value of P is calculated as the ratio of the drug's concentrations in the organic and aqueous phases at equilibrium.
- 2. pKa:** The acid dissociation constant, or pKa, characterizes the extent of ionization of a drug in a solution. It represents the pH at which 50% of the compound exists in its ionized and non-ionized forms. The pKa value is indicative of a drug's ability to donate or accept protons, thus influencing its solubility and stability in different pH conditions.
- 3. Relationship between Partition Coefficient and pKa** The partition coefficient and pKa are interrelated factors that influence dosage form design by determining a drug's solubility and permeability characteristics (Gopinath 2011). The relationship between these factors can be understood as follows
- 4. Solubility and Dissolution:** The solubility of a drug in different media, such as gastrointestinal fluids, is crucial for its dissolution and subsequent absorption. The partition coefficient influences the drug's solubility by dictating its preference for the lipid-rich environment of the cell membranes or the aqueous environment of the dissolution medium. A drug with a higher partition coefficient tends to be more lipophilic, potentially leading to lower solubility in water but improved solubility in lipid-based formulations (Dressman 1998).
- 5. Permeability and Bioavailability** The ability of a drug to cross biological barriers, such as cell membranes, is essential for its bioavailability. Lipophilic drugs with higher partition coefficients generally exhibit better membrane permeability, facilitating efficient absorption into systemic circulation. Consequently, dosage forms can be designed to optimize drug absorption by utilizing appropriate formulation techniques, such as lipid-based delivery systems or prodrug approaches, based on the drug's partition coefficient (Lobenberg 2000, Amidon 1995).
- 6. pH-Dependent Ionization:** The pKa value influences a drug's ionization state at different pH conditions, which can significantly impact its solubility and stability. Drugs with pKa values close to the pH of the target site, such as the stomach or intestines, are likely to exist predominantly in their non-ionized form, thereby enhancing their solubility and permeability. By considering the pKa, dosage forms can be tailored to specific pH

environments, employing appropriate excipients or pH-modifying strategies to optimize drug dissolution and absorption.

The relationship between the partition coefficient and pKa of a drug plays a pivotal role in dosage form design. By understanding the influence of these factors, pharmaceutical scientists can make informed decisions regarding formulation techniques, excipient selection, and pH modulation to enhance drug solubility, permeability, and ultimately, therapeutic efficacy. By considering the interplay between partition coefficient and pKa, innovative dosage forms can be developed to address challenges associated with drug delivery and optimize patient outcomes

IX. CRYSTAL PROPERTIES: POLYMORPHISM

The design of dosage forms plays a crucial role in the successful delivery of drugs to patients. The understanding of drug factors and their relationship with crystal properties, specifically polymorphism, is essential in dosage form design. Polymorphism refers to the ability of a drug molecule to exist in multiple crystalline forms with distinct arrangements of atoms. The presence of polymorphs can significantly impact the drug's physicochemical properties, such as solubility, stability, bioavailability, and therapeutic efficacy. Therefore, a comprehensive understanding of the interplay between drug factors and polymorphism is essential for optimizing dosage form design.

1. Drug Factors Influencing Polymorphism: Several drug-related factors influence the occurrence of polymorphism in pharmaceutical compounds. These factors include:

- **Chemical Structure:** The molecular structure of a drug greatly influences its propensity to exhibit polymorphism. Subtle changes in the arrangement of functional groups or substituents can lead to the formation of different polymorphic forms. For example, the introduction of a methyl group in a drug molecule may result in the formation of a new polymorph.
- **Molecular Flexibility:** The flexibility of a drug molecule affects its ability to adopt different conformations, which can lead to polymorphic variations. Rigid molecules tend to have a lower likelihood of exhibiting polymorphism compared to flexible molecules.
- **Intermolecular Interactions:** Interactions between drug molecules, such as hydrogen bonding, van der Waals forces, and electrostatic interactions, significantly influence the formation of polymorphs. These interactions dictate the packing arrangement of molecules within the crystal lattice, leading to distinct polymorphic forms.
- **Processing Conditions:** The conditions employed during drug synthesis, crystallization, and formulation can impact polymorphism. Factors such as temperature, pressure, solvent choice, and rate of cooling can influence the formation of specific polymorphs. Controlling these processing conditions is critical to obtaining the desired polymorphic form in the final dosage form.

- **Dosage Form Design Considerations:** Dosage form design aims to optimize drug delivery by considering various factors, including polymorphism. The following aspects are relevant when designing dosage forms in relation to crystal properties:
- **Stability and Shelf-Life:** The selection of a stable polymorphic form is crucial to ensure the desired shelf-life and long-term stability of the drug product. Stability studies should be conducted to assess the susceptibility of different polymorphs to transformation under various storage conditions.
- **Bioavailability:** Polymorphism can significantly impact the drug's solubility and dissolution rate, which directly influence its bioavailability. The selection of an appropriate polymorph that exhibits desirable solubility and dissolution characteristics is vital to ensure optimal drug absorption and therapeutic effectiveness.
- **Formulation Compatibility:** Dosage form design should consider the compatibility between the chosen polymorph and the excipients used in the formulation. Certain excipients may promote or inhibit polymorphic transformations, potentially impacting the drug's stability and performance.
- **Manufacturing Processes:** The manufacturing processes employed during dosage form production must be carefully optimized to maintain the desired polymorphic form. Control of processing parameters, such as temperature, pressure, and solvent evaporation rates, is crucial to prevent undesired polymorphic transformations.

The relationship between drug factors, dosage form design, and crystal properties, particularly polymorphism, is a critical aspect of pharmaceutical development. Understanding the influence of drug-related factors on polymorphism enables the selection of the most stable and desirable polymorphic form for dosage form design. By considering factors such as stability, bioavailability, formulation compatibility, and manufacturing processes, pharmaceutical scientists can optimize the design and production of dosage forms, ensuring the effective and safe delivery of drugs to patients

X. STABILITY

Stability is a critical aspect in the design and formulation of pharmaceutical dosage forms. It refers to the ability of a drug product to retain its quality, efficacy, and safety over a specified period under various environmental conditions. Achieving stability is particularly important for ensuring the therapeutic effectiveness of medications throughout their shelf life. In this note, we will explore the interdependence between drug factors and dosage form design with respect to stability, highlighting their significance in pharmaceutical development. Drug factors affecting stability are discussed below under

1. **Chemical Properties:** The inherent chemical characteristics of a drug play a crucial role in determining its stability. Certain drugs are inherently prone to degradation, hydrolysis, oxidation, or photolysis, which can compromise their efficacy and safety. Factors such as pH sensitivity, susceptibility to light, and susceptibility to reactive substances in the environment contribute to chemical instability.

- 2. Solubility and Polymorphism:** Drug solubility is a key consideration in stability. Poorly soluble drugs may undergo precipitation or crystal growth, leading to changes in drug concentration and potential loss of bioavailability. Polymorphism, the ability of a drug to exist in different crystalline forms, can also impact stability by altering dissolution rates, degradation rates, and physical stability.
- 3. Sensitivity to Environmental Conditions:** Drugs can be sensitive to various environmental conditions, including temperature, humidity, and light exposure. Temperature extremes can accelerate degradation processes, while high humidity can induce physical changes, such as agglomeration or moisture uptake, leading to instability. Light-sensitive drugs may undergo photodegradation when exposed to ultraviolet or visible light.
- 4. Excipient Selection:** Excipients play a critical role in dosage form design and stability. Excipients such as binders, disintegrants, lubricants, and antioxidants can influence drug stability by providing protective effects, preventing degradation, or improving drug solubility. The choice of excipients should be based on their compatibility with the drug substance and their ability to maintain stability throughout the product's shelf life.
- 5. Formulation Approaches:** Different dosage forms offer unique advantages in terms of stability. For example, solid dosage forms, including tablets and capsules, can provide protection from moisture and oxygen, reducing the risk of degradation. Additionally, the use of controlled-release formulations can minimize drug degradation by extending the release profile and reducing exposure to harsh environmental conditions.
- 6. Packaging Considerations:** Packaging materials and designs can significantly impact the stability of pharmaceutical products. Light-resistant containers, moisture barrier packaging, and oxygen scavengers can help protect drugs from environmental factors that contribute to instability. Proper packaging selection is crucial to maintain the integrity and stability of the dosage form throughout its shelf life.

The stability of a drug product is influenced by a complex interplay between drug factors and dosage form design. Understanding the chemical properties of the drug, its sensitivity to environmental conditions, and the selection of appropriate excipients, formulation approaches, and packaging materials are crucial in ensuring the stability of pharmaceutical dosage forms. By considering these factors during the formulation and design stages, pharmaceutical scientists can develop stable and effective medications that retain their quality and therapeutic efficacy over an extended period, benefiting patients and healthcare providers alike

XI. ORGANOLEPTIC PROPERTIES

Organoleptic properties significantly impact the patient's acceptance and adherence to pharmaceutical products. For instance, unpleasant taste or odor can lead to non-compliance, particularly in pediatric and geriatric populations. Dosage form design, therefore, must take into account these sensory aspects to ensure patient satisfaction and therapeutic effectiveness. However, the organoleptic properties of a dosage form are influenced by several drug-related factors, which need careful consideration during the formulation process.

Factors Influencing Organoleptic Properties

- 1. Drug Physicochemical Properties:** The physicochemical properties of the drug substance, such as solubility, volatility, and stability, can directly affect its organoleptic attributes. Drugs with a bitter taste or foul odor pose challenges in formulating palatable dosage forms. Solubility and stability issues may necessitate the use of certain excipients or technologies that can impact organoleptic properties.
- 2. Excipients:** Excipients play a crucial role in dosage form design and can significantly influence organoleptic properties. Taste-masking agents, sweeteners, flavoring agents, and odor-masking agents are commonly employed to improve the palatability of oral dosage forms. However, the choice and concentration of excipients must be carefully balanced to ensure compatibility with the drug substance and to avoid potential interactions that could compromise stability or bioavailability.
- 3. Dosage Formulation and Manufacturing Techniques:** The selection of appropriate dosage form and manufacturing techniques can affect the organoleptic properties of a drug product. For example, tablets coated with a taste-masking film can enhance palatability, while the choice of encapsulation materials can influence the release profile and, consequently, the taste and odor perception. Manufacturing processes, such as granulation or spray drying, can also impact the physical characteristics and organoleptic properties of the final product.
- 4. Packaging Materials:** The choice of packaging materials can influence the organoleptic properties of a drug product. For instance, certain plastic containers or closures may interact with the formulation, leading to an alteration in taste or odor. Additionally, light exposure through transparent packaging can cause degradation of photosensitive drugs, affecting both efficacy and sensory attributes.

The organoleptic properties of a dosage form play a pivotal role in patient acceptability and adherence. Considering the interplay between drug factors and dosage form design is crucial to optimize organoleptic attributes. By carefully selecting drug substances, excipients, dosage form formulation techniques, and appropriate packaging materials, pharmaceutical scientists can enhance the sensory experience of patients, ultimately improving therapy outcomes and patient satisfaction. Further research in this area is warranted to develop innovative strategies for dosage form design that effectively address organoleptic challenges and enhance overall patient well-being

XII. OTHER DRUG PROPERTIES

- 1. Pharmacokinetics:** The pharmacokinetic properties of a drug, including absorption, distribution, metabolism, and elimination, are intimately linked to dosage form design. The selection of suitable excipients and formulation techniques can influence drug dissolution, permeation across biological barriers, and systemic exposure, thereby affecting pharmacokinetic behaviour (Mayersohn 1990).
- 2. Drug-Drug Interactions:** Drug properties related to interactions with other drugs, such as solubility, stability, and formulation compatibility, impact dosage form design. In cases

where multiple drugs are co-administered, considerations regarding drug-drug compatibility, potential interactions, and stability in combination must be addressed to ensure therapeutic effectiveness and patient safety.

- 3. Patient Factors:** Patient-related aspects, such as age, sex, disease state, and route of administration preference, must also be considered in dosage form design. For instance, pediatric or geriatric populations may require specific dosage forms tailored to their swallowing capabilities or taste preferences. Furthermore, patients with impaired renal or hepatic function may need dosage forms that consider altered drug metabolism and excretion.

The design of dosage forms is a complex process influenced by various drug factors and their interrelation with other drug properties. Considering the physicochemical properties, stability, drug release profile, and bioavailability of a drug is essential in dosage form design. Furthermore, understanding the interplay between these factors and pharmacokinetics, drug-drug interactions, and patient-related factors is critical for developing safe and effective dosage forms that meet the specific needs of patients. This holistic approach to dosage form design enables optimized drug delivery and enhances therapeutic outcomes

XIII. THERAPEUTIC CONSIDERATIONS IN DOSAGE FORM DESIGN

The design of dosage forms plays a crucial role in ensuring the safe and effective delivery of drugs to patients. Various drug factors significantly influence the design of dosage forms, impacting their therapeutic considerations. This note aims to provide a comprehensive analysis of the interrelationship between drug factors and the design of dosage forms, considering their implications on therapeutic outcomes (Amidon 1995)

- 1. Physicochemical Properties:** The physicochemical properties of a drug have a direct impact on dosage form design. Factors such as solubility, stability, particle size, and polymorphism influence the selection of appropriate formulation strategies. Solubility considerations may lead to the development of solutions, suspensions, or emulsions. Stability concerns can necessitate the use of specific excipients, packaging materials, or formulation techniques. Particle size and polymorphism affect the dissolution and bioavailability of drugs, demanding suitable particle engineering or solid-state modification techniques.
- 2. Drug Release Kinetics:** The desired drug release profile, governed by the pharmacokinetic properties and therapeutic requirements, guides the selection of dosage form design. Immediate-release formulations are suitable for drugs requiring rapid onset of action, while sustained-release or controlled-release formulations are designed to achieve prolonged drug release, reducing dosing frequency and maintaining therapeutic concentrations over an extended period. Factors such as drug solubility, permeability, and metabolism influence the choice of release mechanisms, such as diffusion-controlled, matrix-controlled, or osmotically-driven systems.
- 3. Bioavailability and Absorption:** The bioavailability and absorption characteristics of a drug are critical considerations in dosage form design. Factors influencing these

parameters, such as drug solubility, permeability, efflux transporters, and first-pass metabolism, impact the selection of appropriate formulation strategies. Enhancing solubility through complexation, particle size reduction, or lipid-based formulations can improve drug absorption. Utilizing permeation enhancers, absorption enhancers, or specific drug delivery systems can overcome membrane barriers and maximize bioavailability (Goldberg 1965).

- 4. Targeting and Site-Specific Delivery:** In certain therapeutic scenarios, targeted or site-specific drug delivery becomes imperative. Drug factors such as molecular weight, size, charge, and hydrophobicity influence the selection of targeting strategies. Formulation approaches like liposomes, nanoparticles, prodrugs, or conjugates can be employed to deliver drugs to specific organs, tissues, or cells, enhancing therapeutic efficacy and minimizing systemic side effects. These strategies often require consideration of drug stability, release kinetics, and tissue penetration properties.
- 5. Drug-Excipient Compatibility:** Compatibility between the drug and excipients used in dosage forms is vital to maintain stability, efficacy, and safety. Drug-excipient interactions can affect drug stability, release kinetics, bioavailability, and even patient compliance. Thorough compatibility studies, employing techniques like differential scanning calorimetry (DSC) or Fourier-transform infrared spectroscopy (FTIR), help identify potential interactions and enable appropriate excipient selection and formulation optimization. The design of dosage forms is intricately linked to various drug factors, including physicochemical properties, drug release kinetics, bioavailability and absorption, targeting strategies, and drug-excipient compatibility. Understanding the interplay between these factors and their impact on therapeutic considerations is essential for developing effective and patient-friendly dosage forms. This comprehensive analysis highlights the critical role of drug factors in dosage form design and emphasizes the need for scientific and rational approaches to optimize drug delivery systems for enhanced therapeutic outcomes.

XIV. SUMMARY

Dosage form design plays a crucial role in ensuring the safe and effective delivery of drugs to patients. Various drug factors significantly impact the design and development of dosage forms. This note provides a detailed scientific examination of the relationship between drug factors and dosage form design, highlighting the key considerations and challenges involved (Mayersohn 1990).

- 1. Physicochemical Properties:** The physicochemical properties of a drug, such as solubility, stability, particle size, and crystallinity, profoundly influence dosage form design. These properties dictate the selection of appropriate excipients, formulation techniques, and delivery systems to optimize drug dissolution, absorption, and bioavailability.
- 2. Drug Stability:** The stability of a drug within a dosage form is a critical factor affecting its shelf life and efficacy. Formulation scientists must consider the drug's chemical reactivity, sensitivity to environmental factors (e.g., temperature, humidity, light), and propensity for degradation or polymorphic transformations during storage. Proper

selection of excipients and packaging materials is necessary to ensure drug stability throughout the product's lifecycle.

- 3. Drug Release Kinetics:** The desired drug release profile, whether immediate, sustained, or controlled, is influenced by the drug's pharmacokinetic properties and therapeutic requirements. Factors such as drug solubility, permeability, and desired onset and duration of action guide the selection of suitable release mechanisms (e.g., diffusion, erosion, osmosis) and formulation strategies (e.g., matrix systems, coated particles, liposomes) to achieve the desired drug release kinetics.
- 4. Biopharmaceutical Considerations:** The drug's biopharmaceutical characteristics, including its absorption, distribution, metabolism, and excretion (ADME) profile, significantly impact dosage form design. Factors such as drug solubility, permeability, lipophilicity, and susceptibility to efflux transporters influence the choice of formulation techniques (e.g., self-emulsifying systems, prodrugs) to enhance drug bioavailability and therapeutic efficacy.
- 5. Dose and Potency:** The required dose and potency of a drug also influence dosage form design. High-potency drugs may require specialized containment measures and precise dosage accuracy to ensure patient safety. Additionally, the dosage form must be designed to accommodate the desired dose, taking into account factors such as drug concentration, tablet size, and administration route.
- 6. Patient Factors:** Consideration of patient-specific factors is crucial for dosage form design. Age, weight, disease state, swallowing ability, and preferences (e.g., pediatric, geriatric, dysphagia) influence the selection of appropriate dosage forms (e.g., liquids, tablets, orally disintegrating tablets) and administration routes (e.g., oral, parenteral, transdermal) to ensure optimal drug delivery and patient compliance.

Dosage form design is a complex process that requires a comprehensive understanding of drug factors and their impact on formulation. Physicochemical properties, drug stability, release kinetics, biopharmaceutical considerations, dose and potency requirements, and patient-specific factors must all be carefully evaluated to develop safe, effective, and patient-centric dosage forms. This knowledge aids in the rational design of dosage forms that optimize drug performance and therapeutic outcomes for patients (Lipka 1999).

REFERENCE

- [1] Aulton M.E. 2002. "Pharmaceutics" The Science of dosage forms design, Churchill Livingstone, 295.
- [2] Brahmankar DM, Jaiswal SB. 2015. Biopharmaceutics and Pharmacokinetics Treatise. Vallabh Prakashan, 402-406.
- [3] Finkel R, Clark MA, Cubeddu LX. 2009. Pharmacology. Lippincott Williams & Wilkins, 216-217.
- [4] Ho WH, Lee HLV. 1987. Sustained Drug Delivery Fundamentals and Applications: Design and fabrication of oral controlled release drug delivery system. Marcel Dekker Inc, New York, 373-420.
- [5] Jain NK. 1997. Controlled and novel drug delivery. CBS publishers and distributors, 20-25.
- [6] Kumar KPS, Bhowmik D, Chiranjib and Chandra M, Tripathi KK. 2010. Innovations in sustained release drug delivery systems and its market opportunities. Journal of chemical and pharmaceutical research, 2(1): 349-360.
- [7] Robinson J, Lee VH. 1987. Controlled drug delivery: Fundamentals and applications. CRC Press, 4 -15.

- [8] Robinson J, Lee VH. 2002. Controlled drug delivery: Fundamentals and applications. CRC Press, 903-905.
- [9] Shukla AK, Bishnoi RS, Dev SK, Manish Kumar, Fenin V. 2017. Biopharmaceutical Classification System: Tool based prediction for drug dosage Formulation. *Advance Pharmaceutical Journal*, 2(6): 204-209
- [10] Shukla AK, Bishnoi RS, Kumar M, Fenin V, Jain CP. 2018. Applications of Tamarind seeds Polysaccharide-based copolymers in Controlled Drug Delivery: An overview *Asian Journal of Pharmacy and Pharmacology*, 4(1): 23-30
- [11] Shukla AK, Kumar M, Bishnoi RS, Jain CP. 2017. Review Article Application of Fenugreek Seed Gum: In Novel Drug Delivery *Asian Journal of Biomaterial Research*, 3(6):1-10.
- [12] Tripathi KD. 2009. *Essentials of medical pharmacology*. New Delhi: Jaypee Brothers Medical Publisher, 539-540.
- [13] Vyas SP, Khar RK. 2002. Controlled drug delivery concepts and advances. *Vallabh Prakashan*, 1:411-47.
- [14] Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. *Eur J Pharm Biopharm* 50:47-60.
- [15] Goldberg AH, Gibaldi M, Kanig JL. 1965. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures I - theoretical considerations and discussion of the literature. *J Pharm Sci*. 54:1145-8.
- [16] Lipka E, Amidon GL. 1999. Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. *J Control Release* 62: :41-49.
- [17] Mayersohn M. 1990. Principles of drug absorption. In: Banker GS and Rhodes CT (Eds), *Modern Pharmaceutics*, 2nd ed.. Marcel Dekker. New York. 23-90
- [18] Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharm Res* 12(3): 413-420.
- [19] Dressman JB, Amidon GL, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. *Pharm Res*. 15(1):11-22.
- [20] Lobenberg R, Amidon GL. 2000. Modern bioavailability, bioequivalence and biopharmaceutics classification system new scientific approaches to international regulatory standards. *Eur J Pharm Biopharm* 50:3-12.
- [21] Conradi RA, Burton PS, Borchardt RT. 1996. Physicochemical and biological factors that influence a drug's cellular permeability by passive diffusion. *Methods Princ Med Chem*. 233-252.
- [22] Camenisch G, Folkers G, Van de Waterbeemd H. 1996. review of theoretical passive drug absorption models: historical background, recent developments and limitations. *Pharm Acta Helv* 1:309-327.
- [23] Lennernas H. 1997. Human jejunal effective permeability and its correlation with preclinical drug absorption models. *J Pharm Pharmacol* 49:627-638.
- [24] Goodwin JT, Conradi RA, H.Ho NF, Burton PS. 2001. Physicochemical determinants of passive membrane permeability: role of solute hydrogen-bonding potential and volume. *J Med Chem* 44:3721-3729.
- [25] Charman WN, Porter CJH, Mithani S, 1997. Dressman JB. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. *J Pharm Sci* 86(3):269-282.
- [26] Nai-Ning Songa, Shao-Yu Zhangb , Chang-Xiao Liua. 2004. Overview of factors affecting oral drug absorption. *Asian Journal of Drug Metabolism and Pharmacokinetics* 1-11.
- [27] Banker GS and Rhodes CT: 2008. *Modern Pharmaceutics*. Revised and expanded, Marcel Dekker, Inc. Newyork, Edition 4, vol.121, 167-185.
- [28] Gopinath R, Naidu RAS: 2011. Pharmaceutical preformulation studies- current review. *Int J of Pharm and Biological Archives* 2: 1391-1400.
- [29] Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharm Res*. 12:413-420.